Budenoside/Glycopyrronium/Formoterol clinical trials

Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

This study looks at how a specific inhaler (Budenoside/Glycopyrronium/Formoterol) affects people with COPD in everyday life. For six months, it tracks changes in their symptoms, quality of life, and flare-ups after they start using this medication.